Top Medical News Today
Nationally recognized oncologist Nancy E. Davidson, MD, has accepted the position of Executive Director of Clinical Oncology at the Fred Hutch/University of Washington (UW) Cancer Consortium in Seattle, Washington. Davidson was previously Director of the the University of Pittsburgh Cancer Institute (UPCI).
The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.
Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Puneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.
Patients with low-risk meningioma had a 3-year progression-free survival (PFS) that modestly exceeded expectations after gross total resection followed by observation, results of a cooperative group trial showed.
View More >
Brad S. Kahl, MD, sheds light on the distinctive clinical features of MCL.
Novel Treatment Strategies Emerging for CLL
Jennifer Brown, MD, PhD, director of the CLL Center at the Dana-Farber Cancer Institute and associate professor at Harvard Medical School, discusses the status of targeted therapy agents for the treatment of patients with CLL
Wierda Discusses Current Questions in Frontline CLL Treatment
William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer